{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:31:40Z","timestamp":1793831500086,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Medical Research Project of Health Commission of Nantong","award":["MB2020012"],"award-info":[{"award-number":["MB2020012"]}]},{"name":"the Medical Research Project of Health Commission of Nantong","award":["QNZ2022019"],"award-info":[{"award-number":["QNZ2022019"]}]},{"name":"the Medical Research Project of Health Commission of Nantong","award":["MB2021012"],"award-info":[{"award-number":["MB2021012"]}]},{"name":"the Medical Research Project of Health Commission of Nantong","award":["MB2021012"],"award-info":[{"award-number":["MB2021012"]}]},{"name":"the Medical Research Project of Health Commission of Nantong","award":["MB2021012"],"award-info":[{"award-number":["MB2021012"]}]},{"name":"the Medical Research Project of Health Commission of Nantong","award":["MS2022018"],"award-info":[{"award-number":["MS2022018"]}]},{"name":"the Science and Technology Support Program of Nantong","award":["HS2020005"],"award-info":[{"award-number":["HS2020005"]}]},{"name":"the Science and Technology Support Program of Nantong","award":["JC22022021"],"award-info":[{"award-number":["JC22022021"]}]},{"name":"the Science and Technology Support Program of Nantong","award":["JC2021118"],"award-info":[{"award-number":["JC2021118"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The platelet\/high-density lipoprotein cholesterol ratio (PHR) is a novel inflammatory and hypercoagulability marker that represents the severity of metabolic syndrome. Liver metabolic syndrome is manifested by nonalcoholic fatty liver disease (NAFLD), which is associated with inflammation and hypercoagulability. This cross-sectional investigation aimed to identify the relationship between PHR and NAFLD. Participants in the National Health and Nutrition Examination Survey (NHANES) 2017\u20132020 were evaluated for hepatic steatosis and fibrosis using vibration-controlled transient elastography. The PHR was calculated as the ratio of platelets to high-density lipoprotein cholesterol. Increased PHR was associated with an increased incidence of NAFLD and hepatic fibrosis. Compared with patients in the first PHR quartile, after adjustment for clinical variables, the corresponding odds ratio (OR) for NAFLD in the fourth quartile was 2.36 (95% CI, 1.76 to 3.18) (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.05); however, the OR for hepatic fibrosis was not statistically significant (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&gt;\u20090.05). Furthermore, restricted cubic spline analyses showed an S-shaped association between PHR and NAFLD and an L-shaped relationship between PHR and hepatic fibrosis. The results support the effectiveness of PHR as a marker for NAFLD and hepatic fibrosis. Therefore, interventions to improve the PHR may be of benefit in reducing the incidence of both hepatic steatosis and fibrosis.\n                  <\/jats:p>","DOI":"10.1186\/s12944-023-01861-9","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T15:02:12Z","timestamp":1691766132000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Association between the platelet\/high-density lipoprotein cholesterol ratio and nonalcoholic fatty liver disease: results from NHANES 2017\u20132020"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-0702","authenticated-orcid":false,"given":"Chun-feng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-min","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-mei","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-qin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-xing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"1861_CR1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41575-018-0014-9","volume":"15","author":"VW Wong","year":"2018","unstructured":"Wong VW, Adams LA, de L\u00e9dinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH- current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15:461\u201378.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1861_CR2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323:1175\u201383.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"1861_CR3","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jgh.12212","volume":"28","author":"D Schuppan","year":"2013","unstructured":"Schuppan D, Schattenberg JM. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. J Gastroenterol Hepatol. 2013;28(Suppl 1):68\u201376.","journal-title":"J Gastroenterol Hepatol"},{"key":"1861_CR4","doi-asserted-by":"crossref","first-page":"995749","DOI":"10.3389\/fmed.2022.995749","volume":"9","author":"Q Li","year":"2022","unstructured":"Li Q, Han Y, Hu H, Zhuge Y. Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio has a non-linear association with non-alcoholic fatty liver disease: A secondary prospective cohort study in non-obese Chinese adults. Front Med (Lausanne). 2022;9:995749.","journal-title":"Front Med (Lausanne)"},{"key":"1861_CR5","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/jgh.14989","volume":"35","author":"T Kogiso","year":"2020","unstructured":"Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Long-term outcomes of non-alcoholic fatty liver disease and the risk factors for mortality and hepatocellular carcinoma in a Japanese population. J Gastroenterol Hepatol. 2020;35:1579\u201389.","journal-title":"J Gastroenterol Hepatol"},{"key":"1861_CR6","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","volume":"57","author":"D Kim","year":"2013","unstructured":"Kim D, Kim WR, Kim HJ, Therneau TM. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology. 2013;57:1357\u201365.","journal-title":"Hepatology"},{"key":"1861_CR7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","volume":"61","author":"A Tripodi","year":"2014","unstructured":"Tripodi A, Fracanzani AL, Primignani M, Chantarangkul V, Clerici M, Mannucci PM, Peyvandi F, et al. Procoagulant imbalance in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;61:148\u201354.","journal-title":"J Hepatol"},{"key":"1861_CR8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3390\/biomedicines10020249","volume":"10","author":"A Tripodi","year":"2022","unstructured":"Tripodi A, Lombardi R, Primignani M, La Mura V, Peyvandi F, Fracanzani AL. Hypercoagulability in patients with non-alcoholic fatty liver disease (NAFLD): causes and consequences. Biomedicines. 2022;10:249.","journal-title":"Biomedicines"},{"key":"1861_CR9","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1172\/JCI92744","volume":"127","author":"AK Kopec","year":"2017","unstructured":"Kopec AK, Abrahams SR, Thornton S, Palumbo JS, Mullins ES, Divanovic S, Weiler H, et al. Thrombin promotes diet-induced obesity through fibrin-driven inflammation. J Clin Invest. 2017;127:3152\u201366.","journal-title":"J Clin Invest"},{"key":"1861_CR10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/hepr.13745","volume":"52","author":"N Fujimori","year":"2022","unstructured":"Fujimori N, Kimura T, Tanaka N, Yamazaki T, Okumura T, Kobayashi H, Wakabayashi SI, et al. 2-Step PLT16-AST44 method: Simplified liver fibrosis detection system in patients with non-alcoholic fatty liver disease. Hepatol Res. 2022;52:352\u201363.","journal-title":"Hepatol Res"},{"key":"1861_CR11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/jrms.JRMS_711_16","volume":"22","author":"Z Saremi","year":"2017","unstructured":"Saremi Z, Rastgoo M, Mohammadifard M, Bijari B, Akbari E. Comparison of platelet number and function between nonalcoholic fatty liver disease and normal individuals. J Res Med Sci. 2017;22:75.","journal-title":"J Res Med Sci"},{"key":"1861_CR12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1590\/S0004-28032012000100015","volume":"49","author":"MR Souza","year":"2012","unstructured":"Souza MR, Diniz Mde F, Medeiros-Filho JE, Ara\u00fajo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49:89\u201396.","journal-title":"Arq Gastroenterol"},{"key":"1861_CR13","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.metabol.2016.05.003","volume":"65","author":"N Katsiki","year":"2016","unstructured":"Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65:1109\u201323.","journal-title":"Metabolism"},{"key":"1861_CR14","doi-asserted-by":"crossref","first-page":"100627","DOI":"10.1016\/j.jhepr.2022.100627","volume":"5","author":"L Crudele","year":"2022","unstructured":"Crudele L, De Matteis C, Piccinin E, Gadaleta RM, Cariello M, Di Buduo E, Piazzolla G, et al. Low HDL-cholesterol levels predict hepatocellular carcinoma development in individuals with liver fibrosis. JHEP Rep. 2022;5:100627.","journal-title":"JHEP Rep"},{"issue":"1","key":"1861_CR15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13098-021-00741-5","volume":"13","author":"S Karami","year":"2021","unstructured":"Karami S, Poustchi H, Sarmadi N, Radmard AR, Ali Yari F, Pakdel A, Shabani P. Association of anti-oxidative capacity of HDL with subclinical atherosclerosis in subjects with and without non-alcoholic fatty liver disease. Diabetol Metab Syndr. 2021;13(1):121.","journal-title":"Diabetol Metab Syndr"},{"key":"1861_CR16","doi-asserted-by":"crossref","first-page":"e3403","DOI":"10.1002\/dmrr.3403","volume":"37","author":"I Jialal","year":"2021","unstructured":"Jialal I, Jialal G, Adams-Huet B. The platelet to high density lipoprotein -cholesterol ratio is a valid biomarker of nascent metabolic syndrome. Diabetes Metab Res Rev. 2021;37:e3403.","journal-title":"Diabetes Metab Res Rev"},{"issue":"155","key":"1861_CR17","first-page":"1","volume":"2","author":"LR Curtin","year":"2012","unstructured":"Curtin LR, Mohadjer LK, Dohrmann SM, Montaquila JM, Kruszan-Moran D, Mirel LB, Carroll MD, et al. The National Health and Nutrition Examination Survey: Sample Design, 1999\u20132006. Vital Health Stat. 2012;2(155):1\u201339.","journal-title":"Vital Health Stat"},{"key":"1861_CR18","doi-asserted-by":"crossref","first-page":"154752","DOI":"10.1016\/j.metabol.2021.154752","volume":"121","author":"S Ciardullo","year":"2021","unstructured":"Ciardullo S, Perseghin G. Statin use is associated with lower prevalence of advanced liver fbrosis in patients with type 2 diabetes. Metabolism. 2021;121:154752.","journal-title":"Metabolism"},{"key":"1861_CR19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/joim.13069","volume":"288","author":"B Zou","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, non-obese and lean NAFLD in the United States, 1999\u20132016. J Intern Med. 2020;288:139\u201351.","journal-title":"J Intern Med"},{"key":"1861_CR20","doi-asserted-by":"crossref","first-page":"16494","DOI":"10.1038\/srep16494","volume":"5","author":"J Wang","year":"2015","unstructured":"Wang J, Xu C, Xun Y, Lu Z, Shi J, Yu C, et al. ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. Sci Rep. 2015;5:16494.","journal-title":"Sci Rep"},{"key":"1861_CR21","doi-asserted-by":"crossref","first-page":"1058779","DOI":"10.3389\/fimmu.2022.1058779","volume":"13","author":"Y Song","year":"2022","unstructured":"Song Y, Guo W, Li Z, Guo D, Li Z, Li Y. Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015\u20132018. Front Immunol. 2022;13:1058779.","journal-title":"Front Immunol"},{"key":"1861_CR22","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2021.12.034","volume":"20","author":"I Graupera","year":"2022","unstructured":"Graupera I, Thiele M, Serra-Burriel M, Caballeria L, Roulot D, Wong GL, et al. Low accuracy of FIB-4 and NAFLD Fibrosis Scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20:2567\u20132576.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1861_CR23","doi-asserted-by":"crossref","first-page":"925690","DOI":"10.3389\/fimmu.2022.925690","volume":"13","author":"R Xie","year":"2022","unstructured":"Xie R, Xiao M, Li L, Ma N, Liu M, Huang X, Liu Q, et al. Association between SII and hepatic steatosis and liver fibrosis: a population-based study. Front Immunol. 2022;13:925690.","journal-title":"Front Immunol"},{"key":"1861_CR24","doi-asserted-by":"crossref","first-page":"857110","DOI":"10.3389\/fendo.2022.857110","volume":"13","author":"R Xie","year":"2022","unstructured":"Xie R, Liu M. Relationship between non-alcoholic fatty liver disease and degree of hepatic steatosis and bone mineral density. Front Endocrinol (Lausanne). 2022;13:857110.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"1861_CR25","doi-asserted-by":"crossref","first-page":"e24225","DOI":"10.1002\/jcla.24225","volume":"36","author":"N Yang","year":"2022","unstructured":"Yang N, Lu Y, Cao L, Lu M. The association between non-alcoholic fatty liver disease and serum ferritin levels in American adults. J Clin Lab Anal. 2022;36(2):e24225.","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"1861_CR26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jhep.2007.11.020","volume":"48","author":"D Roulot","year":"2008","unstructured":"Roulot D, Czernichow S, Le Cl\u00e9siau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol. 2008;48(4):606\u201313.","journal-title":"J Hepatol"},{"key":"1861_CR27","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/aje\/kwr265","volume":"175","author":"N Orsini","year":"2012","unstructured":"Orsini N, Li R, Wolk A, Khudyakov P, Spiegelman D. Meta-analysis for linear and nonlinear dose-response relations: examples, an evaluation of approximations, and software. Am J Epidemiol. 2012;175:66\u201373.","journal-title":"Am J Epidemiol"},{"key":"1861_CR28","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/hep4.2069","volume":"6","author":"T Arai","year":"2022","unstructured":"Arai T, Atsukawa M, Tsubota A, Mikami S, Haruki U, Yoshikata K, Ono H, et al. Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatol Commun. 2022;6:3073\u201382.","journal-title":"Hepatol Commun"},{"key":"1861_CR29","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264\u20131281.e4.","journal-title":"Gastroenterology"},{"key":"1861_CR30","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ultrasmedbio.2010.07.005","volume":"36","author":"M Sasso","year":"2010","unstructured":"Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, Sandrin L, et al. Controlled attenuation parameter (CAP): a novel VCTE\u2122 guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825\u201335.","journal-title":"Ultrasound Med Biol"},{"key":"1861_CR31","doi-asserted-by":"crossref","first-page":"e41964","DOI":"10.1371\/journal.pone.0041964","volume":"7","author":"BK Kim","year":"2012","unstructured":"Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, Chon CY, Park YN, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fibrosis in Asian subjects with chronic hepatitis B. PLoS ONE. 2012;7:e41964.","journal-title":"PLoS ONE"},{"key":"1861_CR32","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908\u201322.","journal-title":"Nat Med"},{"key":"1861_CR33","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","volume":"313","author":"ME Rinella","year":"2015","unstructured":"Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263\u201373.","journal-title":"JAMA"},{"key":"1861_CR34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/gutjnl-2018-317666","volume":"68","author":"Y Chang","year":"2019","unstructured":"Chang Y, Ryu S, Sung KC, Cho YK, Sung E, Kim HN, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. Gut. 2019;68:1667\u201375.","journal-title":"Gut"},{"key":"1861_CR35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.bcmd.2008.07.003","volume":"42","author":"M El Haouari","year":"2009","unstructured":"El Haouari M, Rosado JA. Platelet function in hypertension. Blood Cells Mol Dis. 2009;42:38\u201343.","journal-title":"Blood Cells Mol Dis"},{"key":"1861_CR36","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3390\/ijerph17031101","volume":"17","author":"KH Cho","year":"2020","unstructured":"Cho KH, Park HJ, Kim JR. Decrease in serum HDL-C Level is associated with elevation of blood pressure: Correlation analysis from the Korean National Health and Nutrition Examination Survey 2017. Int J Environ Res Public Health. 2020;17:1101.","journal-title":"Int J Environ Res Public Health"},{"key":"1861_CR37","first-page":"100736","volume":"22","author":"E Nanizawa","year":"2020","unstructured":"Nanizawa E, Tamaki Y, Sono R, Miyashita R, Hayashi Y, Kanbe A, Ito H, et al. Short-term high-fat diet intake leads to exacerbation of concanavalin A-induced liver injury through the induction of pro-coagulation state. Biochem Biophys Rep. 2020;22:100736.","journal-title":"Biochem Biophys Rep"},{"key":"1861_CR38","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1080\/17461391.2019.1571114","volume":"19","author":"P Farzanegi","year":"2019","unstructured":"Farzanegi P, Dana A, Ebrahimpoor Z, Asadi M, Azarbayjani MA. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): Roles of oxidative stress and inflammation. Eur J Sport Sci. 2019;19:994\u20131003.","journal-title":"Eur J Sport Sci"},{"key":"1861_CR39","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jhep.2018.11.034","volume":"70","author":"S de Oliveira","year":"2019","unstructured":"de Oliveira S, Houseright RA, Graves AL, Golenberg N, Korte BG, Miskolci V, Huttenlocher A. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish. J Hepatol. 2019;70:710\u201321.","journal-title":"J Hepatol"},{"issue":"1","key":"1861_CR40","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1038\/s41467-018-06929-0","volume":"9","author":"TK Soderborg","year":"2018","unstructured":"Soderborg TK, Clark SE, Mulligan CE, Janssen RC, Babcock L, Ir D, Young B, et al. The gut microbiota in infants of obese mothers increases inflammation and susceptibility to NAFLD. Nat Commun. 2018;9(1):4462.","journal-title":"Nat Commun"},{"key":"1861_CR41","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2006.02.011","volume":"44","author":"JW Haukeland","year":"2006","unstructured":"Haukeland JW, Dam\u00e5s JK, Konopski Z, L\u00f8berg EM, Haaland T, Goverud I, Torjesen PA, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol. 2006;44:1167\u201374.","journal-title":"J Hepatol"},{"key":"1861_CR42","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.cgh.2019.01.027","volume":"17","author":"S Pelusi","year":"2019","unstructured":"Pelusi S, Cespiati A, Rametta R, Pennisi G, Mannisto V, Rosso C, Baselli G, et al. Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis. Clin Gastroenterol Hepatol. 2019;17:2310\u20132319.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1861_CR43","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cvr\/cvu137","volume":"103","author":"M van der Stoep","year":"2014","unstructured":"van der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res. 2014;103:362\u201371.","journal-title":"Cardiovasc Res"},{"key":"1861_CR44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.26510","volume":"59","author":"A Verrijken","year":"2014","unstructured":"Verrijken A, Francque S, Mertens I, Prawitt J, Caron S, Hubens G, Van Marck E, et al. Prothrombotic factors in histologically proven nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2014;59:121\u20139.","journal-title":"Hepatology"},{"key":"1861_CR45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/liv.14417","volume":"40","author":"PT Campbell","year":"2020","unstructured":"Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, et al. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int. 2020;40:1111\u201320.","journal-title":"Liver Int"},{"issue":"8","key":"1861_CR46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3390\/cells7080085","volume":"7","author":"N Bitto","year":"2018","unstructured":"Bitto N, Liguori E, La Mura V. Coagulation, microenvironment and liver fibrosis. Cells. 2018;7(8):85.","journal-title":"Cells"},{"key":"1861_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2022.111710","volume":"101","author":"E Nanizawa","year":"2022","unstructured":"Nanizawa E, Otsuka S, Hatayama N, Tamaki Y, Hayashi Y, Ishikawa T, Hirai S, et al. Short-term high-fat and high-carbohydrate diets increase susceptibility to liver injury by inducing hepatic procoagulant and proinflammatory conditions with different balances. Nutrition. 2022;101: 111710.","journal-title":"Nutrition"},{"key":"1861_CR48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhepr.2019.10.001","volume":"1","author":"P Ramadori","year":"2019","unstructured":"Ramadori P, Klag T, Malek NP, Heikenwalder M. Platelets in chronic liver disease, from bench to bedside. JHEP Rep. 2019;1:448\u201359.","journal-title":"JHEP Rep"},{"key":"1861_CR49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s00535-011-0436-4","volume":"46","author":"M Yoneda","year":"2011","unstructured":"Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, Ono M, Eguchi Y, et al. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:1300\u20136.","journal-title":"J Gastroenterol"},{"key":"1861_CR50","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2169\/internalmedicine.9853-17","volume":"57","author":"Y Ikarashi","year":"2018","unstructured":"Ikarashi Y, Kodama K, Taniai M, Hashimoto E, Tokushige K. The Clinical Difference in the Platelet Counts between Liver Cirrhosis with Nonalcoholic Fatty Liver Disease and Hepatitis C Virus. Intern Med. 2018;57:1065\u201370.","journal-title":"Intern Med"},{"key":"1861_CR51","doi-asserted-by":"crossref","first-page":"5849","DOI":"10.3748\/wjg.v26.i38.5849","volume":"26","author":"N Gotlieb","year":"2020","unstructured":"Gotlieb N, Schwartz N, Zelber-Sagi S, Chodick G, Shalev V, Shibolet O. Longitudinal decrease in platelet counts as a surrogate marker of liver fibrosis. World J Gastroenterol. 2020;26:5849\u201362.","journal-title":"World J Gastroenterol"},{"key":"1861_CR52","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s10620-006-9144-y","volume":"52","author":"Z Karasu","year":"2007","unstructured":"Karasu Z, Tekin F, Ersoz G, Gunsar F, Batur Y, Ilter T, Akarca US. Liver fibrosis is associated with decreased peripheral platelet count in patients with chronic hepatitis B and C. Dig Dis Sci. 2007;52:1535\u20139.","journal-title":"Dig Dis Sci"},{"key":"1861_CR53","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.25772","volume":"56","author":"R Loomba","year":"2012","unstructured":"Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, Bass NM. Nonalcoholic Steatohepatitis Clinical Research Network. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943\u201351.","journal-title":"Hepatology"},{"key":"1861_CR54","first-page":"1795851","volume":"2021","author":"BH Rao","year":"2021","unstructured":"Rao BH, Nair P, Koshy AK, Krishnapriya S, Greeshma CR, Venu RP. Role of high-density lipoprotein cholesterol (HDL-C) as a clinical predictor of decompensation in patients with chronic liver disease (CLD). Int J Hepatol. 2021;2021:1795851.","journal-title":"Int J Hepatol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-023-01861-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T19:23:08Z","timestamp":1700248988000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-023-01861-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1861"],"URL":"https:\/\/doi.org\/10.1186\/s12944-023-01861-9","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"16 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NHANES is conducted by the Centers for Disease Control and Prevention (CDC) and the National Center for Health Statistics (NCHS). The NCHS Research Ethics Review Committee reviewed and approved the NHANES study protocol. All participants signed written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"130"}}